Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.



RECOVERY Collaborative Group, , Horby, Peter W ORCID: 0000-0002-9822-1586, Peto, Leon, Staplin, Natalie, Campbell, Mark, Pessoa-Amorim, Guilherme, Mafham, Marion, Emberson, Jonathan R ORCID: 0000-0001-7792-9422, Stewart, Richard, Prudon, Benjamin
et al (show 23 more authors) (2024) Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Nature communications, 15 (1). 924-.

Access the full-text of this item by clicking on the Open Access link.

Abstract

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome.

Item Type: Article
Uncontrolled Keywords: RECOVERY Collaborative Group, Humans, Treatment Outcome, Hospitalization, Adult, Hospitals, Dimethyl Fumarate, COVID-19, SARS-CoV-2
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences
Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences > School of Medicine
Faculty of Health and Life Sciences > Institute of Infection, Veterinary and Ecological Sciences
Depositing User: Symplectic Admin
Date Deposited: 20 Mar 2024 16:21
Last Modified: 20 Mar 2024 16:21
DOI: 10.1038/s41467-023-43644-x
Open Access URL: https://doi.org/10.1038/s41467-023-43644-x
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3179748